<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00804427</url>
  </required_header>
  <id_info>
    <org_study_id>SU-12042008-1358</org_study_id>
    <nct_id>NCT00804427</nct_id>
  </id_info>
  <brief_title>Effect of Fish Oil on Plasma Triglycerides in Adults</brief_title>
  <official_title>Effect of Fish Oil as an Ethyl Ester or Triglyceride Preparation on Plasma Triglycerides in Hypertriglyceridemic Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Naturals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this small, short pilot study is to determine the feasibility (e.g.,&#xD;
      recruitment, dose acceptance, retention) of a future longer trial comparing the effects of&#xD;
      two types of omega-3 fats from fish oil on plasma triglycerides. The two types of fish oil&#xD;
      are composed of (1) omega-3 fatty acids in triglyceride form; and (2) as esterified free&#xD;
      fatty acids (i.e. ethyl esters). Although these two types of fish oil supplements are&#xD;
      available to the public, it remains unclear whether they are equally effective in lowering&#xD;
      plasma triglycerides.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a double-blinded, parallel design, placebo controlled trial with three active&#xD;
      treatment arms to compare the triglyceride (TG) lowering effects of the same dose of EPA and&#xD;
      DHA provided in three formulations of supplements that differ in the proportion of omega-3 FA&#xD;
      present as ethyl esters vs. triglycerides. The active therapy for each of the three fish oil&#xD;
      supplementation arms is 4 g/day of combined EPA and DHA provided as: a) 90% TG formulation,&#xD;
      b) 60% TG formulation, or c) ethyl esters (esterified fatty acids)(i.e., 0% TG). The placebo&#xD;
      was a soy oil supplement with an identical total fat content. The primary outcome is the&#xD;
      12-week change in TG concentrations in the active groups vs. placebo. Secondary outcomes&#xD;
      include LDL particle distribution, defined as either subclasses LDL1, LDL2, LDL3 and LDL4,&#xD;
      and LDL subclass phenotype patterns A, B, or A/B.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Triglycerides at 3 months</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Change was calculated as the value at 3 months minus the value at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in LDL particle concentration (LDL1, LDL2, LDL3, LDL4) at 3 months</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Change was calculated as the value at 3 months minus the value at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in LDL phenotype pattern (A, B, or A/B) at 3 months</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Change was calculated as the number (and percent) of participants who improved their LDL phenotype pattern at 3 months.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Fish oil (90% triglycerides)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fish oil (4 grams/day of combined EPA and DHA) as 90% triglyceride formulation, taken in two divided doses with main meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish oil (60% triglycerides)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fish oil (4 grams/day of combined EPA and DHA) as 60% triglyceride formulation, taken in two divided doses with main meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish oil (ethyl esters)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fish oil (4 grams/day of combined EPA and DHA) as ethyl esters formulation (0% triglycerides), taken in two divided doses with main meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soy oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Soy oil supplement with identical total fat content, taken in two divided doses with main meals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil (90% triglycerides)</intervention_name>
    <arm_group_label>Fish oil (90% triglycerides)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil (60% triglycerides)</intervention_name>
    <arm_group_label>Fish oil (60% triglycerides)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil (ethyl esters)</intervention_name>
    <arm_group_label>Fish oil (ethyl esters)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soy oil</intervention_name>
    <arm_group_label>Soy oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:*Gender: Both women and men&#xD;
&#xD;
          -  Age: &gt; or = 18 years&#xD;
&#xD;
          -  Ethnicity and race: All ethnic and racial backgrounds welcome&#xD;
&#xD;
          -  Fasting blood triglycerides greater than or equal to 150 mg/dL&#xD;
&#xD;
          -  Planning to be available for clinic visits for the 12 weeks of study participation&#xD;
&#xD;
          -  Ability and willingness to give written informed consent&#xD;
&#xD;
          -  No known active psychiatric illness. Exclusion Criteria:*At screening:&#xD;
&#xD;
          -  Daily intake of dietary supplements containing omega-3 FAs within the past month.&#xD;
&#xD;
          -  Fasting blood glucose greater than or equal to 126 mg/dL&#xD;
&#xD;
          -  Self reported personal history of:&#xD;
&#xD;
          -  Clinically significant atherosclerosis (e.g., CAD, PAD)&#xD;
&#xD;
          -  Malignant neoplasm&#xD;
&#xD;
          -  Subjects currently receiving the following medications (self report):&#xD;
&#xD;
          -  Lipid lowering drugs including statins&#xD;
&#xD;
          -  Anti-hypertensive drugs: beta-blockers and thiazides&#xD;
&#xD;
          -  Body Mass Index (BMI) greater than or equal to 40.&#xD;
&#xD;
          -  Pregnant or Lactating&#xD;
&#xD;
          -  Inability to communicate effectively with study personnel&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher D Gardner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Oelrich B, Dewell A, Gardner CD. Effect of fish oil supplementation on serum triglycerides, LDL cholesterol and LDL subfractions in hypertriglyceridemic adults. Nutr Metab Cardiovasc Dis. 2013 Apr;23(4):350-7. doi: 10.1016/j.numecd.2011.06.003. Epub 2011 Sep 15.</citation>
    <PMID>21924882</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2008</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Christopher Gardner</investigator_full_name>
    <investigator_title>Professor of Medicine (Research)</investigator_title>
  </responsible_party>
  <keyword>Fish oil</keyword>
  <keyword>Triglycerides</keyword>
  <keyword>Low-density Lipoprotein (LDL) cholesterol</keyword>
  <keyword>Low-density Lipoprotein (LDL) subclass</keyword>
  <keyword>Low-density Lipoprotein (LDL) particle size</keyword>
  <keyword>Low-density Lipoprotein (LDL) phenotype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

